ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
तुलना करने के लिए मीट्रिक्स | PROK | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPROKपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.8x | −3.0x | −0.5x | |
PEG अनुपात | −1.57 | −0.10 | 0.00 | |
क़ीमत/बुक | −0.7x | 7.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 966.4x | 8.7x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 140.6% | 62.3% | 51.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.4% | 7.1% | अनलॉक करें |